Study of Paxlovid for children with COVID-19 underway at Norton Children’s Research Institute

Norton Children’s Research Institute, affiliated with the UofL School of Medicine, is involved in a study of nirmatrelvir/ritonavir (authorized as Paxlovid in older children and adults) in symptomatic pediatric outpatients with COVID-19 who are at risk of progression to severe illness.

Norton Children’s Research Institute, affiliated with the UofL School of Medicine, is involved in a study to evaluate the safety, pharmacokinetics and efficacy of nirmatrelvir/ritonavir (authorized as Paxlovid in older children and adults) in symptomatic pediatric outpatients with COVID-19 who are at risk of progression to severe illness. All participants will receive the study medication, which is taken orally twice a day for five days. Participants’ total time in the study will be about five weeks.

For providers with access to Norton Healthcare’s Epic medical records system, there is a best practice alert (BPA) in Epic to help identify potential participants from general pediatric practices, emergency departments and Norton Immediate Care Centers. If you see the BPA, please consider referring the patient to our research team to evaluate their eligibility for the study, NCT05261139.

A screenshot of the BPA for the Paxlovid for children study is shown

Current COVID-19-related clinical trials and studies at Norton Children’s


Get Our Monthly Newsletter

Stay informed on the latest offerings and treatments available at Norton Healthcare by subscribing to our monthly enewsletter.

Subscribe

Make a Referral

Partnering with you in caring for your patients.

Refer a Patient
Are You a Patient?
Provider Spotlight

Adam M. Skaff, M.D.

Adam M. Skaff, M.D., has joined Norton Children’s Heart Institute, affiliated with the UofL School of Medicine, as a pediatric cardiologist.

Read More

Search our entire site.